sunitinib malate — United Healthcare
meningiomas (central nervous system cancer)
Initial criteria
- Diagnosis of surgically inaccessible meningiomas
- AND disease is recurrent OR disease is progressive
- AND further radiation is not possible
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Sutent therapy
Approval duration
12 months